COVID-19
-
One-and-done COVID-19 drug successful
A single dose of lambda-interferon reduced hospitalization among COVID-19 outpatients in a late-stage study spearheaded by a Stanford Medicine virologist.
-
New way to treat COVID-19 smell loss
In a trial led by Stanford Medicine researchers, more than half of patients with persistent smell loss saw improvement with injections of platelet-rich plasma.
-
How COVID-19 virus infects nasal cells
A discovery by Stanford Medicine researchers and colleagues may pave the way for a “morning after” or prophylactic nasal spray to prevent infection.
-
Predicting immunity from vaccination
A gene signature seen in antibody-producing cells in the blood of vaccinated study participants could expedite vaccine development.
-
Awards for COVID-19 project, media work
A COVID-19 remembrance project, two videos, an article about bad brain cells and Stanford Medicine magazine have been recognized by the Council for Advancement and Support of Education.
-
Antivirals may benefit some inpatients
Elevated virus levels in hospitalized COVID-19 patients’ blood predicts worsening respiratory symptoms and suggests ongoing viral replication in later disease stages, Stanford Medicine-led study says.
-
COVID-19 virus can infect fat tissue
Stanford Medicine scientists’ findings could explain why obese people have a higher risk of SARS-CoV-2 infection and are more likely to progress to severe disease and die of infection.
-
Viral genome packing key in replication
Disrupting a virus’s genome packaging can halt replication and jumpstart a natural immune response against subsequent exposures, a Stanford Medicine study finds.
-
Mark Davis on immunology research
Vaccinology has taken great leaps forward in the past decade, largely due to advanced analytical methods as well as a shift in researchers’ focus from rodents to humans.
-
Hints into long COVID
People with lower levels of an antiviral antibody as well as those with lung disease take longer to clear COVID-19 symptoms, say Stanford Medicine researchers.
-
Gummy phlegm and COVID-19
Levels of a stringy, spongy substance soar in the sputum of COVID-19 patients requiring intubation, accounting for at least some of their breathing trouble. Development of an off-patent drug may prevent it.
- Administration
- Aging
- Big Data
- Biochemistry
- Bioengineering
- Cancer
- Cardiovascular Health
- Chemical Biology
- Chronic Disease
- COVID-19
- Developmental Biology
- Education
- Genetics
- Global Health
- Health Policy
- Hearing
- Imaging
- Immunology
- Infectious Disease
- Mental Health
- Neuroscience
- Nutrition
- Obituaries
- Pain
- Patient Care
- Pediatrics
- Precision Health
- Preventive Medicine
- Sleep
- Stem Cells
- Surgery
- Technology
- Transplantation
- Urology
- Women's Health